<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0122-0667</journal-id>
<journal-title><![CDATA[Revista Médica de Risaralda]]></journal-title>
<abbrev-journal-title><![CDATA[Revista médica Risaralda]]></abbrev-journal-title>
<issn>0122-0667</issn>
<publisher>
<publisher-name><![CDATA[Universidad Tecnológica de Pereira]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0122-06672020000200148</article-id>
<article-id pub-id-type="doi">10.22517/25395203.24439</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diabetes mellitus asociada al uso crónico de antipsicóticos atípicos]]></article-title>
<article-title xml:lang="en"><![CDATA[Diabetes mellitus association with chronic use of atypical antipsychotics]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejos Narváez]]></surname>
<given-names><![CDATA[Álvaro Argoty]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chamorro]]></surname>
<given-names><![CDATA[Giovanny Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez López]]></surname>
<given-names><![CDATA[Laura Melissa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Universitaria Ciencias de la Salud Facultad de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria Ciencias de la Salud  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación Universitaria Ciencias de la Salud  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>26</volume>
<numero>2</numero>
<fpage>148</fpage>
<lpage>153</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0122-06672020000200148&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0122-06672020000200148&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0122-06672020000200148&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los agentes antipsicóticos son considerados como el principal tratamiento farmacológico para el manejo de mantenimiento y el tratamiento de casos agudos de la esquizofrenia y otros trastornos mentales. Estos medicamentos están clasificados en dos grupos: los antipsicóticos de primera generación o antipsicóticos típicos (AT) y los antipsicóticos de segunda generación o antipsicóticos atípicos (AA). En relación con el uso de los antipsicóticos típicos (AT), se han descrito importantes efectos adversos, sobre todo síntomas extrapiramidales (EPS), lo cual ha relegado su uso y fomenta el mayor empleo en la práctica clínica de los antipsicóticos atípicos (AA) gracias a la adecuada efectividad clínica demostrada hasta el momento. Sin embargo, estos medicamentos están asociados con diferentes alteraciones metabólicas, entre las cuales se encuentra un mayor riesgo de diabetes; para lo cual se han propuesto varios mecanismos etiopatogénicos. En esta revisión narrativa, se presenta un resumen actualizado de la literatura de los últimos 5 años sobre el uso de antipsicóticos atípicos y la diabetes mellitus tipo 2, haciendo énfasis en las diferentes hipótesis reportadas hasta el momento que involucran el aumento de peso y diferentes efectos mediados por hormonas, receptores de neurotransmisores y neuropéptidos que impactan en la génesis de los estados hiperglucémicos y de insulinorresistencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Antipsychotic agents are currently considered as the main pharmacological treatment that helps the maintenance management of acute schizophrenia and other mental disorders. These drugs are classified into two groups: First-generation antipsychotics (FGAs) or typical antipsychotics, and Second-generation antipsychotics (SGAs) also known as atypical antipsychotics (AAP). In relation to the use of typical antipsychotics, some relevant adverse effects have been described, especially in terms of extrapyramidal side effects (EPS), which has downgraded their use and encourages the treatment of atypical antipsychotics (AAP) due to the adequate clinical effectiveness demonstrated so far in the practice. However, these drugs have been associated with different metabolic alterations such as the increased risk of suffering from diabetes; thus, several etiopathogenic mechanisms have been proposed. In this narrative review, we seek to present an updated summary of the literature of the last five years about the use of atypical antipsychotics and type 2 diabetes mellitus. Here it has been emphasized the different hypotheses reported so far that involve weight gain and different effects mediated by hormones, neurotransmitter receptors, and neuropeptides that impact on the genesis of hyperglycemia and insulin resistance states]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[antipsicóticos]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[efectos adversos a largo plazo]]></kwd>
<kwd lng="es"><![CDATA[reacciones adversas]]></kwd>
<kwd lng="en"><![CDATA[Antipsychotic agents]]></kwd>
<kwd lng="en"><![CDATA[type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[long term adverse effects]]></kwd>
<kwd lng="en"><![CDATA[Drug-Related Side Effects and Adverse Reactions]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grajales]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Valverde]]></surname>
<given-names><![CDATA[ÁM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain]]></article-title>
<source><![CDATA[Cells]]></source>
<year>2019</year>
<volume>8</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1336</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[TRE]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<source><![CDATA[The Maudsley prescribing guidelines in psychiatry]]></source>
<year>2018</year>
<publisher-name><![CDATA[John Wiley &amp; Sons]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whicher]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Holt]]></surname>
<given-names><![CDATA[RIG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation]]></article-title>
<source><![CDATA[Eur. J.of Endocrinol]]></source>
<year>2018</year>
<volume>178</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>R245-R58</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between antipsychotic medication use and diabetes]]></article-title>
<source><![CDATA[Curr. Diab. Rep]]></source>
<year>2019</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>96</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Kirk]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms]]></article-title>
<source><![CDATA[Pharmacology &amp; therapeutics]]></source>
<year>2010</year>
<volume>125</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>169-79</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sjo]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Stenstrøm]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Bojesen]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Frølich]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Bilenberg]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of metabolic syndrome in drug-naive adolescents after 12 months of second-generation antipsychotic treatment]]></article-title>
<source><![CDATA[J. Child. Adolesc. Psychopharmacol]]></source>
<year>2017</year>
<volume>27</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>884-91</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galling]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gerhard]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Carbon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[JAMA psychiatry]]></source>
<year>2016</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>247-59</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ingimarsson]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[MacCabe]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Haraldsson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jónsdóttir]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sigurdsson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland]]></article-title>
<source><![CDATA[Nordic journal of psychiatry]]></source>
<year>2017</year>
<volume>71</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>496-502</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burghardt]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Seyoum]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mallisho]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burghardt]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Kowluru]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies]]></article-title>
<source><![CDATA[Progress in Neuro-Psychopharmacology and Biological Psychiatry]]></source>
<year>2018</year>
<volume>83</volume>
<page-range>55-63</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[You]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis]]></article-title>
<source><![CDATA[BMC psychiatry]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yood]]></surname>
<given-names><![CDATA[MU]]></given-names>
</name>
<name>
<surname><![CDATA[DeLorenze]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Quesenberry]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveria]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[A-L]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose]]></article-title>
<source><![CDATA[BMC psychiatry]]></source>
<year>2011</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>197</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katsiki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mikhailidis]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Banach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leptin, cardiovascular diseases and type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Acta Pharmacologica Sinica]]></source>
<year>2018</year>
<volume>39</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1176-88</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albaugh]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Singareddy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mauger]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2011</year>
<volume>6</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rice]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hankinson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Clevenger]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulating prolactin concentrations and risk of type 2 diabetes in US women]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2018</year>
<volume>61</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2549-60</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[X-F]]></given-names>
</name>
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular mechanisms of antipsychotic drug-induced diabetes]]></article-title>
<source><![CDATA[Frontiers in neuroscience]]></source>
<year>2017</year>
<page-range>11:643</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weston-Green]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[X-F]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor]]></article-title>
<source><![CDATA[CNS drugs]]></source>
<year>2013</year>
<volume>27</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1069-80</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bathina]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[UN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brain-derived neurotrophic factor and its clinical implications]]></article-title>
<source><![CDATA[Archives of medical science: AMS]]></source>
<year>2015</year>
<volume>11</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1164</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farino]]></surname>
<given-names><![CDATA[ZJ]]></given-names>
</name>
<name>
<surname><![CDATA[Morgenstern]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maffei]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quick]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Solis]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wiriyasermkul]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New roles for dopamine D 2 and D 3 receptors in pancreatic beta cell insulin secretion]]></article-title>
<source><![CDATA[Molecular psychiatry]]></source>
<year>2019</year>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canfrán-Duque]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Casado]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Pastor]]></surname>
<given-names><![CDATA[Ó]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Wandelmer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de la Peña]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lerma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro]]></article-title>
<source><![CDATA[Journal of lipid research]]></source>
<year>2013</year>
<volume>54</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>310-24</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vuk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rojnic Kuzman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baretic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Matovinovic Osvatic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature]]></article-title>
<source><![CDATA[Psychiatria Danubina]]></source>
<year>2017</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>121-35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
